DAVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Endava PLC (DAVA) is not a strong buy for a beginner, long-term investor at this time. The stock's technical indicators show mixed signals, with bearish moving averages and overbought RSI levels. The financial performance is weak, with significant declines in revenue, net income, and EPS. Options data indicates a neutral to slightly bearish sentiment. Analyst ratings have been downgraded with reduced price targets, and there are no recent positive news catalysts or congress trading data to support a buy decision. Given the user's impatience and preference for long-term investment, holding off on this stock is recommended until there are clearer signs of recovery or growth.
The MACD is positive and expanding, indicating short-term bullish momentum. However, the RSI is at 72.759, suggesting the stock is nearing overbought levels. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, indicating a longer-term downtrend. Key resistance levels are at 5.394 and 5.676, while support levels are at 4.482 and 4.2.
No significant positive catalysts identified. The MACD histogram is positive, and the stock has short-term bullish momentum.
Weak financial performance with YoY declines in revenue (-5.88%), net income (-200.80%), and EPS (-218.18%). Analyst ratings have been downgraded with reduced price targets. No recent news or congress trading data to support a bullish case. Stock trend analysis suggests a likelihood of further declines in the short to medium term.
In Q2 2026, revenue dropped by -5.88% YoY to $184.1M. Net income fell significantly to -$6.91M (-200.80% YoY), and EPS declined to -0.13 (-218.18% YoY). Gross margin also decreased to 20.42%, down -11.29% YoY, indicating worsening profitability.
Analysts have lowered price targets recently. TD Cowen reduced the target to $6.50 from $8, JPMorgan reduced it to $9 from $10, and Guggenheim reduced it to $13 from $15. The consensus is neutral to hold, with some analysts citing undemanding valuation and healthy free cash flow but expecting incremental improvements to take time.
